Cardiac cell repair therapy: A clinical perspective

Bernard J. Gersh, Robert D. Simari, Atta Behfar, Carmen M Terzic, Andre Terzic

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

From bone marrow transplants 5 decades ago to the most recent stem cell-derived organ transplants, regenerative medicine is increasingly recognized as an emerging core component of modern practice. In cardiovascular medicine, innovation in stem cell biology has created curative solutions for the treatment of both ischemic and nonischemic cardiomyopathy. Multiple cell-based platforms have been developed, harnessing the regenerative potential of various natural and bioengineered sources. Clinical experience from the first 1000 patients (approximately) who have received stem cell therapy worldwide indicates a favorable safety profile with modest improvement in cardiac function and structural remodeling in the setting of acute myocardial infarction or chronic heart failure. Further investigation is required before early adoption and is ongoing. Broader application in practice will require continuous scientific advances to match each patient with the most effective reparative phenotype, while ensuring optimal cell delivery, dosing, and timing of intervention. An interdisciplinary effort across the scientific and clinical community within academia, biotechnology, and government will drive the successful realization of this next generation of therapeutic agents for the "broken" heart.

Original languageEnglish (US)
Pages (from-to)876-892
Number of pages17
JournalMayo Clinic Proceedings
Volume84
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Transplants
Regenerative Medicine
Biotechnology
Cardiomyopathies
Cell Biology
Heart Failure
Bone Marrow
Myocardial Infarction
Medicine
Phenotype
Safety
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cardiac cell repair therapy : A clinical perspective. / Gersh, Bernard J.; Simari, Robert D.; Behfar, Atta; Terzic, Carmen M; Terzic, Andre.

In: Mayo Clinic Proceedings, Vol. 84, No. 10, 2009, p. 876-892.

Research output: Contribution to journalArticle

Gersh, Bernard J. ; Simari, Robert D. ; Behfar, Atta ; Terzic, Carmen M ; Terzic, Andre. / Cardiac cell repair therapy : A clinical perspective. In: Mayo Clinic Proceedings. 2009 ; Vol. 84, No. 10. pp. 876-892.
@article{572b58c1beff4e18a91b63bb404a8146,
title = "Cardiac cell repair therapy: A clinical perspective",
abstract = "From bone marrow transplants 5 decades ago to the most recent stem cell-derived organ transplants, regenerative medicine is increasingly recognized as an emerging core component of modern practice. In cardiovascular medicine, innovation in stem cell biology has created curative solutions for the treatment of both ischemic and nonischemic cardiomyopathy. Multiple cell-based platforms have been developed, harnessing the regenerative potential of various natural and bioengineered sources. Clinical experience from the first 1000 patients (approximately) who have received stem cell therapy worldwide indicates a favorable safety profile with modest improvement in cardiac function and structural remodeling in the setting of acute myocardial infarction or chronic heart failure. Further investigation is required before early adoption and is ongoing. Broader application in practice will require continuous scientific advances to match each patient with the most effective reparative phenotype, while ensuring optimal cell delivery, dosing, and timing of intervention. An interdisciplinary effort across the scientific and clinical community within academia, biotechnology, and government will drive the successful realization of this next generation of therapeutic agents for the {"}broken{"} heart.",
author = "Gersh, {Bernard J.} and Simari, {Robert D.} and Atta Behfar and Terzic, {Carmen M} and Andre Terzic",
year = "2009",
doi = "10.4065/84.10.876",
language = "English (US)",
volume = "84",
pages = "876--892",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Cardiac cell repair therapy

T2 - A clinical perspective

AU - Gersh, Bernard J.

AU - Simari, Robert D.

AU - Behfar, Atta

AU - Terzic, Carmen M

AU - Terzic, Andre

PY - 2009

Y1 - 2009

N2 - From bone marrow transplants 5 decades ago to the most recent stem cell-derived organ transplants, regenerative medicine is increasingly recognized as an emerging core component of modern practice. In cardiovascular medicine, innovation in stem cell biology has created curative solutions for the treatment of both ischemic and nonischemic cardiomyopathy. Multiple cell-based platforms have been developed, harnessing the regenerative potential of various natural and bioengineered sources. Clinical experience from the first 1000 patients (approximately) who have received stem cell therapy worldwide indicates a favorable safety profile with modest improvement in cardiac function and structural remodeling in the setting of acute myocardial infarction or chronic heart failure. Further investigation is required before early adoption and is ongoing. Broader application in practice will require continuous scientific advances to match each patient with the most effective reparative phenotype, while ensuring optimal cell delivery, dosing, and timing of intervention. An interdisciplinary effort across the scientific and clinical community within academia, biotechnology, and government will drive the successful realization of this next generation of therapeutic agents for the "broken" heart.

AB - From bone marrow transplants 5 decades ago to the most recent stem cell-derived organ transplants, regenerative medicine is increasingly recognized as an emerging core component of modern practice. In cardiovascular medicine, innovation in stem cell biology has created curative solutions for the treatment of both ischemic and nonischemic cardiomyopathy. Multiple cell-based platforms have been developed, harnessing the regenerative potential of various natural and bioengineered sources. Clinical experience from the first 1000 patients (approximately) who have received stem cell therapy worldwide indicates a favorable safety profile with modest improvement in cardiac function and structural remodeling in the setting of acute myocardial infarction or chronic heart failure. Further investigation is required before early adoption and is ongoing. Broader application in practice will require continuous scientific advances to match each patient with the most effective reparative phenotype, while ensuring optimal cell delivery, dosing, and timing of intervention. An interdisciplinary effort across the scientific and clinical community within academia, biotechnology, and government will drive the successful realization of this next generation of therapeutic agents for the "broken" heart.

UR - http://www.scopus.com/inward/record.url?scp=70350484991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350484991&partnerID=8YFLogxK

U2 - 10.4065/84.10.876

DO - 10.4065/84.10.876

M3 - Article

C2 - 19797777

AN - SCOPUS:70350484991

VL - 84

SP - 876

EP - 892

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -